| 1 |
33455494 | Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19. | 2021 Apr |
1 |
| 2 |
30992242 | Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. | 2019 Jun |
1 |
| 3 |
28057172 | Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8. | 2016 Oct - Dec |
5 |
| 4 |
22886551 | Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2. | 2012 Sep |
3 |
| 5 |
16648389 | CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. | 2006 Aug |
1 |
| 6 |
17010942 | Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions. | 2006 Dec 15 |
1 |
| 7 |
12844133 | Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. | 2003 Jul |
1 |
| 8 |
11875364 | Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. | 2002 Mar |
2 |
| 9 |
11875365 | Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. | 2002 Mar |
3 |
| 10 |
10681382 | CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. | 2000 Mar |
7 |
| 11 |
11038161 | Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. | 2000 Nov |
1 |
| 12 |
9578596 | Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. | 1998 May 1 |
6 |
| 13 |
9735164 | Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. | 1998 Sep 15 |
1 |
| 14 |
10022751 | An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. | 1998 Apr |
2 |
| 15 |
8613906 | Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. | 1996 Apr |
1 |
| 16 |
8274418 | Cortisol metabolism in vitro--III. Inhibition of microsomal 6 beta-hydroxylase and cytosolic 4-ene-reductase. | 1993 Dec |
1 |